NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
- Conditions
- Extensive Stage Small Cell Lung CancerRecurrent Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00773955
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
- Conditions
- Male Breast CarcinomaStage IIA Breast Cancer AJCC v6 and v7Stage IIIC Breast Cancer AJCC v7Stage IIB Breast Cancer AJCC v6 and v7Stage IIIA Breast Cancer AJCC v7Stage IIIB Breast Cancer AJCC v7
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 305
- Registration Number
- NCT00770809
- Locations
- 🇺🇸
Dana-Farber Cancer Institute at Boston Medical Center - Brighton, Brighton, Massachusetts, United States
🇺🇸Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸Sparks Regional Medical Center, Fort Smith, Arkansas, United States
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
- Conditions
- Breast Ductal Carcinoma In Situ
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2014
- Registration Number
- NCT00769379
- Locations
- 🇺🇸
Northeast Alabama Regional Medical Center, Anniston, Alabama, United States
🇺🇸Providence Hospital, Mobile, Alabama, United States
🇺🇸University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
- Conditions
- Adult Nasal Type Extranodal NK/T-cell LymphomaAngioimmunoblastic T-cell LymphomaNodal Marginal Zone B-cell LymphomaCutaneous B-cell Non-Hodgkin LymphomaAdult Grade III Lymphomatoid GranulomatosisAnaplastic Large Cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell Lymphoma
- Interventions
- Other: positron emission tomographyOther: laboratory biomarker analysisOther: pharmacological studyOther: pharmacogenomic studies
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2014-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00769288
- Locations
- 🇺🇸
Wayne State University, Detroit, Michigan, United States
Nortriptyline for Idiopathic Gastroparesis
- Conditions
- Idiopathic Gastroparesis
- Interventions
- Drug: Placebo (for nortriptyline)
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2020-05-14
- Target Recruit Count
- 130
- Registration Number
- NCT00765895
- Locations
- 🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸University of Michigan Medical Center, Ann Arbor, Michigan, United States
Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
- Conditions
- Stage I Colon CancerStage IIIC Rectal CancerAdenomatous PolypStage I Rectal CancerStage IIC Colon CancerRecurrent Colon CancerStage IIA Rectal CancerStage IIB Colon CancerStage IIIA Colon CancerStage IIB Rectal Cancer
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2015-01-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT00754494
- Locations
- 🇺🇸
VA Long Beach Healthcare System, Long Beach, California, United States
🇺🇸Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
- Conditions
- Ovarian Steroid Cell TumorMalignant Ovarian Epithelial TumorOvarian Sex Cord-Stromal TumorOvarian GynandroblastomaOvarian Granulosa Cell TumorOvarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell TypesOvarian Sertoli-Leydig Cell TumorOvarian Sex Cord Tumor With Annular Tubules
- Interventions
- Biological: BevacizumabOther: Laboratory Biomarker Analysis
- First Posted Date
- 2008-09-08
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00748657
- Locations
- 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Acute Myeloid LeukemiaAdult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Interventions
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 95
- Registration Number
- NCT00742625
- Locations
- 🇺🇸
Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States
🇺🇸Florida Hospital, Orlando, Florida, United States
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
- Conditions
- Solid NeoplasmAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin Lymphoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2008-08-25
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 81
- Registration Number
- NCT00740805
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- Conditions
- Weight LossEatingObesityElectric Stimulation Therapy
- Interventions
- Other: Sham/no-stimulationDevice: Transcranial Direct Current Stimulation (TDCS)
- First Posted Date
- 2008-08-21
- Last Posted Date
- 2025-06-17
- Target Recruit Count
- 148
- Registration Number
- NCT00739362
- Locations
- 🇺🇸
NIDDK, Phoenix, Phoenix, Arizona, United States